Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 11/20 | 0.41 |
| ▸ | CA1 | P00915 | 8/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 10/20 | 0.40 |
| ▸ | CA12 | O43570 | 7/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6513053 | 0.84 | CA2 (0.47) | CA2CA1CA4CA7CA9 | |
| SCHEMBL28282439 | 0.76 | CA2 (0.52) | CA2CA1CA4CA7CA9 | |
| SCHEMBL6512570 | 0.73 | PTGS2 (0.44) | PTGS2POLBKDM4E | |
| SCHEMBL6512506 | 0.73 | PTGS2 (0.66) | CA2CA1CA4CA7CA9 | |
| SCHEMBL16707354 | 0.69 | MAPT (0.49) | KDM4E | |
| SCHEMBL11128848 | 0.66 | PTGS1 (0.51) | KMT2AKDM4E | |
| SCHEMBL9842300 | 0.66 | KAT6A (0.42) | CA2CA1CA4CA7CA9 | |
| SCHEMBL6512655 | 0.66 | CHEK2 (0.49) | — | |
| SCHEMBL7464854 | 0.66 | CHEK2 (0.68) | — | |
| SCHEMBL6517910 | 0.65 | CA2 (0.54) | CA2CA1CA4CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040157824-A1 | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents | PFIZER INC. | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157824-A1 | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents | CNR1, PTGS1, PTGER1 | CA2 459/4885CA1 1790/4885CA4 808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.